Apeiron Biologics AG
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Apeiron Biologics AG
Coronavirus Notebook: EMA Begins Assessing AZ’s Evusheld, Apeiron Starts Phase I Trial Of Inhaled APN01
The UK has explained its strategy for administering COVID-19 vaccines to people who have been partially immunized abroad.
EU passes legislation allowing VAT exemption for coronavirus vaccines to make them more affordable, as two treatments for severe disease and “Long COVID” respectively enter Phase II trials.
Bristol makes its own deal with Celgene ally Dragonfly, while Gilead ends virology partnerships with Durect and Precision BioSciences.
Dozens of life science companies are working to find effective treatments for COVID-19. In addition to our daily in-depth coverage of key regulatory events relating to the coronavirus pandemic, we’re bringing you selected brief insights into some of the efforts that are under way on this front.
- Other Names / Subsidiaries
- invIOs GmbH
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.